Bringing Allogeneic Cell Therapies to More Patients

June 7, 2023

Allogeneic (allo) cell therapies offer substantial benefits to patients due to their efficacy and availability. However, giving patients access to these treatments presents obstacles at the manufacturing level. Donor screening and recruiting is key to the process of building a sufficient supply chain. Doing so begins with a large donor pool.

According to the authors, “To secure a sustainable donor supply, manufacturers should start from a large donor registry and use broad selection criteria to avoid narrowing the donor pool too soon. Requirements related solely to gender, age, and blood type alone may decrease the available donor pool by at least 75%, and each additional screening requirement will shrink the donor pool even further. In addition, manufacturers should establish their overall supply chain network capabilities (e.g., cryo shipment, temperature monitoring) and partners well in advance of commercialization. Manufacturers’ supply chain strategy must also include mitigation plans to ensure the cells stay viable if there are any delays in transferring the collected cells to the manufacturing site.”

To read more, click here.

(Source: Cell and Gene, May 1st, 2023)

Share This Story!